The increasing evidence supported the role of Enhancer of Zeste Homolog 2 (EZH2) in the cancer development and progression. However, its precise role in the tumorigenesis of Nasopharyngeal Carcinoma (NPC) remains to be elucidated. EZH2 was depleted by retroviral infection in the NPC cells (HK-1, CNE-2, CNE-1 and C666-1). The degree of EZH2 knockdown was then assessed by real-time quantitative PCR and Western Blot analysis. Cell proliferation was assessed using the soluble tetrazolium salt (MTS) cell proliferation assay, and cell cycle was measured by FACS test. The methylation status of p16 INK4a was determined by bisulphate treatment of the DNA, followed by MSP. EZH2 was over-expressed in NPC cells, and the expression in undifferentiated-derived NPC cells (CNE-1, C666-1) was more significant than differentiated-derived NPC cells (HK-1, CNE-2). EZH2 was successfully depleted after retroviral infection in C666-1 cells, and the EZH2 depletion could inhibit the proliferation and arrested G1/S phase of NPC cells. In addition, both mRNA and protein levels of p16 INK4a increased significantly in presence of EZH2 depletion. The further Methylation-Specific Polymerase Chain Reaction (MSP) assay suggested that over-expressed EZH2 may contribute to the reduction of p16 INK4a expression by hyper methylating its promoter. EZH2 is overexpressed in NPC and reduces expression of p16 INK4a by influencing methylation, opening therapeutic options.
Introduction
Nasopharyngeal Carcinoma (NPC) is a head and neck cancer, which occurs with high frequency in Asian populations, especially among people of Cantonese ancestry. There is increasing evidence supports that environmental factors and genetic susceptibility play important roles in NPC pathogenesis, especially, the Epstein-Barr virus in particular has been implicated in the molecular abnormalities leading to NPC (1) (2) (3) . Enhancer of Zeste Homolog 2 (EZH2) is a subunit of the Polycomb-Repressive Complex 2 (PRC2), which catalyses the trimethylation of histone H3 on Lys 27 (H3K27) and represses gene transcription. Moreover, EZH2 could form a co-repressor complex with histone deacetylase 1, 2 (HDAC1, 2) and alter gene promoter activities by influencing the histone methylation (4) . EZH2 was found to be frequently overexpressed in a variety of carcinomas including prostate and breast cancer. Overexpression of EZH2 has been demonstrated to involve in the invasion and progression of malignant cancer, especially in the progression of prostate cancer. Some studies recently showed that proliferation of tumor cells could be inhibited significantly after downregulation of EZH2 (5) . In recent studies, it is reported that EZH2 frequently overexpressed and associated with poor prognosis in NPC and associated with a higher risk of relapse in NPC patients. However, the corresponding role of EZH2 in the development of NPC was not clear (6, 7) .
The absence of p16 INK4a is also important to NPC. Patients with NPC tumors with low p16 levels have a worse prognosis because this is associated with decreased radio sensitivity and higher rates of tumor recurrence (8, 9) . It is suggested that pretreatment of NPC patients with p16 INK4a gene therapy before radiation can improve outcomes.
In our study, we reported that overexpression of EZH2 played an important role in the proliferation of NPC. The EZH2 depletion inhibited growth of NPC and suppressed the progress of S phase significantly. Moreover, the EZH2 depletion could rescue the expression of p16 through demethylating promoter of it. It is suggested that EZH2 may a therapeutic target to improve the radiation outcome by upregulation of p16 INK4a expression.
Methods and Materials

Cell Culture and Retroviral Infection
Nasopharyngeal carcinoma cell line CNE-1, CNE-2, C666-1, HK-1 and Hela cell were maintained in RPMI 1640 with 10% fetal bovine serum. For EZH2 knockdown, the sequences of the two different 21-nucleotide shRNAs targeting the human EZH2 sequence were previously described (10) . Sense and antisense oligonucleotides were annealed to form duplexes and inserted into the pSIREN-Retro Q retroviral vector (BD Biosciences Clontech), according to the manufacturer's recommendations. Briefly, plasmids containing EZH2 or control shRNA were transfected into GP2 packaging cells to produce the virus. Viral supernatant was concentrated by centrifugation at 20,000 rpm for 60 min. Infect cells were selected for puromycin (1 mg/ml) resistance for a week. The degree of EZH2 knockdown was then assessed by real-time quantitative PCR and Western blot analysis.
Real-Time Quantitative Reverse Transcriptase-PCR
For gene expression assays, firstly, we extracted RNA using Trizol (Invitrogen, CA), quantified it spectrophotometrically, and used it as the substrate for RT reactions to generate single-stranded. After cDNA got, we performed real-time PCR with reagents and protocols from the Applied Biosystems SYBR Green master mix kit. We performed all PCR reactions using an ABI Prism 7900 instrument (Applied Biosystems). We used human GAPDH as an internal loading control for quantitative RT-PCR. We compared human EZH2, and p16 mRNA levels and we normalized them to the GAPDH mRNA level. The primers for amplifying GAPDH, EZH2 and p16 were as follows: GAPDH forward, 5-TGC CTC CTG CAC CAC CAA CT-3, and reverse, 5-CCC GTT CAG CTC AGG GAT GA-3; EZH2 forward, 5-GCC AGA CTG GGA AGA AAT CTG-3, and reverse, 5-TGT GTT GGA AAA TCC AAG TCA-3; p16 forward, 5-GTG AGA GTG GCG GGG TC-3, and reverse, 5-GTT ACG GTC GGA GGC CG-3.
Western-Blot
At 48 h after EZH2 shRNA-virus infection, protein was extracted with RIPA containing protease inhibitor cocktail. We loaded 30 mg proteins in each lane on the polyacrylamide gel. We incubated membranes for overnight at four degrees with an appropriate dilution of the primary antibody followed by incubation with the horseradish peroxidaseconjugated second antibody and visualized them using the enhanced chemiluminescence substrate kit (Amersham Biosciences, Inc.). The primary antibodies used were polyclonal antibodies against EZH2 (#3147, Cell Signal Tech), H3K27-me3 (#9756, Cell Signaling Tech), p16 INK4a (#4824, Cell Signaling Tech), GAPDH (#2118, Cell Signaling Tech).
Proliferation and Cell Cycle Analysis
Cell proliferation was assessed using the soluble tetrazolium salt (MTS) cell proliferation assay as previously described (11) , Briefly, 20 ml of the MTS reagent (Promega, Madison, WI, USA) was added to each well in a 96-well plate at the indicated time points, and absorbance was measured at 492 nm. To measure the cell cycle, cells were collected and washed twice in FACS buffer. Cells were resuspended in FACS buffer, and then ice-cold 70% ethanol was added to fix the cells for 2 h on ice. Cells were washed once, before resuspending in FACS buffer containing 100 mg/ml RNAse A and 50 mg/ml propidium iodine. Cells were incubated at room temperature for 30 min in the dark before being analyzed on FACS (Becton Dickinson Instrument).
Methylation-Specific Polymerase Chain Reaction (MSP)
The methylation status of p16 INK4a was determined by bisulphite treatment of the DNA, followed by MSP, as described previously (12) . The following primer sequences were used: Methylated, forward, 5-TTA TTA GAG GGT GGG GCG GAT CGC-3; reverse, 5-GAC CCC GAA CCG CGA CCG TAA-3; Unmethylated, forward, 5-TTA TTA GAG GGT GGG GTG GAT TGT-3; reverse, 5-CAA CCC CAA ACC ACA ACC ATAA-3.
Statistical Analysis
Statistical analysis was performed using the SPSS statistical software package (standard version 19.0). The migrated cells were determined using a two-tailed Student's t test. P values from a two-tailed test were ,0.05 were considered statistically significant.
Results
EZH2 Overexpressed in Nasopharyngeal Carcinoma Cells
EZH2 has been demonstrated to be frequently overexpressed in a variety of carcinomas including prostate and breast cancer. In this study, we performed western-blot to test whether EZH2 overexpressed in Nasopharyngeal Carcinoma Cells (NPCs). There are four NPC cell lines, namely HK-1, CNE-2, CNE-1 and C666-1 were used in this study. HK-1 and CNE-2 were derived from differentiated NPCs, whereas the CNE-1 and C666-1 were from undifferentiated NPCs. Our results showed that EZH2 overexpressed in all of four NPC cell lines. In addition, the expression of EZH2 in undifferentiated-derived NPC cells (CNE1, C666-1) was nearly two times more than in differentiated-derived NPC cells (HK-1, CNE-2) ( Figure 1) . The Hela was used as a positive control cell, which has been reported overexpressed EZH2 previously. The overexpression of EZH2 led us to investigate its function in the development of NPC.
Validation of Knockdown of EZH2 by shRNA Treatment
The effect of EZH2 shRNA knockdown was tested by both real-time PCR and western-blot analysis. The results showed that EZH2 expression on both mRNA and protein levels was diminished significantly on days 2 after EZH2 shRNA infected C666-1 cells ( Figure 2) . Moreover, the Figure 2B showed the expression of tri-methylation H3K27 was decreased evidently, which is mainly maintained by EZH2.
EZH2 Depletion Inhibited the Proliferation and Arrested G1/S Phase of Nasopharyngeal Carcinoma Cells
It has been reported that increased expression of EZH2 had been associated with invasive growth and aggressive clinical behavior in variety of tumors. In order to investigate role of EZH2 in the proliferation of NPC, we performed the soluble tetrazolium salt (MTS) cell proliferation assay. The results showed that growth of C666-1 cells was suppressed significantly after EZH2 shRNA treatment (p , 0.05). Figure 3 indicated proliferation of C666-1 cells was inhibited evidently on days 4 after EZH2 knockdown. Inhibition of cell proliferation was usually associated with cell cycle arrest. In this study, we analyzed the cell cycle kinetics through flow cytometry assay. We found that C666-1 cells were arrested at G1/S stage, the percent of cells at G1/S increased by 10%, after EZH2 depletion. Figure 3B showed that percent of S phase was decreased by 10% at the day 2 of EZH2 knock down ( Figure 3B ).
EZH2 Regulated Expression of p16
p16 INK4a , a Cyclin-Dependent Kinase (CDK) inhibitor protein, played critical roles in the G1/S cell cycle transition. As above data, it is showed that depletion of EZH2 induced the C666-1 cells arrest at G1/S checkpoint. Whether EZH2 could regulate the expression p16 INK4a followed by involved in progression of S phase is unclear. In our study, we found that both mRNA and protein levels of p16 INK4a increased significantly in presence of EZH2 depletion (Figure 2A, B) . The data in Figure 2A and B indicate that p16 may be a downstreaming target of EZH2. However, the mechanism of interaction between them is unknown. Methylation Specific Polymerase Chain Reaction (MSP) analysis showed that depletion of EZH2 reduced the methylation of p16 INK4a promoter significantly, compared to the control (Figure 4) . The results suggest that over-expressed EZH2 may contribute to the reduction of p16 INK4a expression by hypermethylating its promoter.
Discussion
Nasopharyngeal carcinoma (NPC) is a subset of head and neck epithelial cancers, treated by radiation therapy for early disease, but combined with chemotherapy for more advanced stages. Unfortunately, the majority of NPC is diagnosed at an advanced stage because of nonspecific presenting symptoms. In light of this, more targeted treatments of NPC need to be developed. To do so, the molecular changes that lead to NPC tumorigenesis must first be clarified. p16 is a Cyclin-Dependent Kinase Inhibitory Protein (CKI) that suppresses activity and is frequently inactivated in cancer (13) . Therefore, loss of p16 results in cyclin D1 overactivation and subsequent increases in G1/S phase transitions (14) . However, in head and neck cancers, including NPC, this is not the case, as the majority of head and neck cancers exhibit low p16 levels. Kwok-Wai et al. demonstrated that hypermethylation of the 5′ CpG Island can serve as a mechanism for inactivation of the p16 INK4a gene in NPC tumor. The aberrant methylation of the 5′ CpG island of the p16 INK4a gene was found 6 (22%) of 27 primary tumors, but not in normal tissues of the nasopharynx (15) . p16 INK4a preferentially display its tumour-suppressive function through binding and inactivating cyclin-dependent kinase. There are multiple epigenetic and genetic mechanisms for silencing its tumour-suppressive processes required for the development of malignant tumours. Recently, the EZH2 proteins were reported to be involved in silencing tumour suppressive processes (16) . In our study, we found that EZH2 overexpressed in the four NPC cell lines and involved in promoting growth of these cells. Furthermore, the aberrant EZH2 inhibited expression of p16 INK4a significantly. DNA methylation is an important process for the dysfunction of the target gene in cancer. A recent report documented that EZH2 interacts with DNA methyltransferases and is associated with methyltransferase activities (17) . We examined the DNA methylation status of p16 INK4a in this process of EZH2 knockdown. The methylated p16 promoter was diminished after EZH2 shRNA treatment, suggesting that EZH2 is closely related to the methylation of the p16 INK4a promoter and its maintenance. NPC, especially the undifferentiated NPC was almost associated with Epstein-Barr virus (EBV) infection. The viral oncoprotein LMP1 (latent membrane protein 1) of EBV was usually involved in the hypermethylation of certain cellular promoter by inducing DNA methyltransferases 1, 3a, and 3b. EBV could increase the occurrence of CDH1 hypermethylation, further to promote metastasis of the disease, when the tumor expresses LMP1 (18) (19) (20) . Here, we have the evidence to hypothesis that LMP1 may increase methylation of p16 promoter by promoting expression of EZH2 in NPC.
Conclusion
This data showed that aberrant expression EZH2 overexpression and involved in progression of NPC. Tumour suppressor gene p16 INK4a was increased through demethylation of its promoter by depleting EZH2 expression. It is suggested EZH2 could be a potential therapeutic target in management of NPC patients with p16 INK4a Hypermethylation.
